![](media/image1.png){width="5.972916666666666in"
height="0.4791666666666667in"}

Top of Form

## Complete Summary

#### TITLE

Morbidity of radiological procedures: percentage of patients undergoing
percutaneous transpleural biopsy of the lung or mediastinum, for whom
there is documented evidence of pneumothorax and/or haemothorax
requiring intervention following the procedure, during the 6 month
period.

#### SOURCE(S)

Australian Council on Healthcare Standards (ACHS). ACHS clinical
indicator users\' manual 2008. ULTIMO NSW: Australian Council on
Healthcare Standards (ACHS); 2007 Dec. 776 p.

### Measure Domain

#### PRIMARY MEASURE DOMAIN

Outcome

The validity of measures depends on how they are built. By examining the
key building blocks of a measure, you can assess its validity for your
purpose. For more information, visit the [Measure
Validity](http://www.qualitymeasures.ahrq.gov/resources/measure_domains.aspx)
page.

#### SECONDARY MEASURE DOMAIN

Does not apply to this measure

### Brief Abstract

#### DESCRIPTION

This measure is used to assess the percentage of patients undergoing
percutaneous transpleural biopsy of the lung or mediastinum, for whom
there is documented evidence of pneumothorax and/or haemothorax
requiring intervention following the procedure, during the 6 month time
period.

#### RATIONALE

Percutaneous transpleural biopsy may be associated with significant
morbidity and may reflect possible problems in the performance of the
procedure.

#### PRIMARY CLINICAL COMPONENT

Percutaneous transpleural biopsy of the lung or mediastinum;
pneumothorax; haemothorax

#### DENOMINATOR DESCRIPTION

Total number of patients undergoing percutaneous transpleural biopsy of
the lung or mediastinum, during the 6 month time period (see the related
\"Denominator Inclusions/Exclusions\" field in the Complete Summary)

#### NUMERATOR DESCRIPTION

Total number of patients undergoing percutaneous transpleural biopsy of
the lung or mediastinum, for whom there is documented evidence of
pneumothorax and/or haemothorax requiring intervention following the
procedure, during the 6 month time period (see the related \"Numerator
Inclusions/Exclusions\" field in the Complete Summary)

### Evidence Supporting the Measure

#### EVIDENCE SUPPORTING THE CRITERION OF QUALITY

-   A formal consensus procedure involving experts in relevant clinical,
    methodological, and organizational sciences

### Evidence Supporting Need for the Measure

#### NEED FOR THE MEASURE

Use of this measure to improve performance

#### EVIDENCE SUPPORTING NEED FOR THE MEASURE

Australian Council on Healthcare Standards (ACHS). Australian clinical
indicator report 1998-2006. Determining the potential to improve quality
of care: 8th edition. ULTIMO NSW: Australian Council on Healthcare
Standards (ACHS); 2007. 564 p.

### State of Use of the Measure

#### STATE OF USE

Current routine use

#### CURRENT USE

Internal quality improvement

### Application of Measure in its Current Use

#### CARE SETTING

Hospitals

#### PROFESSIONALS RESPONSIBLE FOR HEALTH CARE

Physicians

#### LOWEST LEVEL OF HEALTH CARE DELIVERY ADDRESSED

Single Health Care Delivery Organizations

#### TARGET POPULATION AGE

Unspecified

#### TARGET POPULATION GENDER

Either male or female

#### STRATIFICATION BY VULNERABLE POPULATIONS

Unspecified

### Characteristics of the Primary Clinical Component

#### INCIDENCE/PREVALENCE

Unspecified

#### ASSOCIATION WITH VULNERABLE POPULATIONS

Unspecified

#### BURDEN OF ILLNESS

Unspecified

#### UTILIZATION

Unspecified

#### COSTS

Unspecified

### Institute of Medicine National Healthcare Quality Report Categories

#### IOM CARE NEED

Getting Better

#### IOM DOMAIN

Safety

### Data Collection for the Measure

#### CASE FINDING

Users of care only

#### DESCRIPTION OF CASE FINDING

Patients undergoing percutaneous transpleural biopsy of the lung or
mediastinum, during the 6 month time period

#### DENOMINATOR SAMPLING FRAME

Patients associated with provider

#### DENOMINATOR INCLUSIONS/EXCLUSIONS

**Inclusions**\
Total number of patients undergoing percutaneous transpleural biopsy of
the lung or mediastinum, during the 6 month time period

-   This indicator relates to the treatment of both inpatients and
    outpatients having percutaneous transpleural biopsy of the lung or
    mediastinum performed.

-   Any patient having a subsequent percutaneous transpleural biopsy of
    the lung is to be counted as a new patient.

**Exclusions**\
This indicator excludes the performance of biopsy of the pleura or
pleural drainage.

#### RELATIONSHIP OF DENOMINATOR TO NUMERATOR

All cases in the denominator are equally eligible to appear in the
numerator

#### DENOMINATOR (INDEX) EVENT 

Diagnostic Evaluation

#### DENOMINATOR TIME WINDOW

Time window is a single point in time

#### NUMERATOR INCLUSIONS/EXCLUSIONS

**Inclusions**\
Total number of patients undergoing percutaneous transpleural biopsy of
the lung or mediastinum, for whom there is documented evidence of
pneumothorax\* and/or haemothorax\*\* requiring intervention following
the procedure, during the 6 month time period

\*Pneumothorax is defined as the presence of air in the pleural cavity
following the procedure, on the first post procedural chest x-ray\*\*\*.

\*\*Haemothorax is defined as the presence of, or an increase in, the
amount of fluid in the pleural cavity following the procedure, on the
first post procedural chest x-ray\*\*\*.

\*\*\*The first post procedural chest x-ray is defined as occurring from
1 to 4 hours after the percutaneous transpleural biopsy.

**Exclusions**\
Unspecified

#### MEASURE RESULTS UNDER CONTROL OF HEALTH CARE PROFESSIONALS, ORGANIZATIONS AND/OR POLICYMAKERS

The measure results are somewhat or substantially under the control of
the health care professionals, organizations and/or policymakers to whom
the measure applies.

#### NUMERATOR TIME WINDOW

Encounter or point in time

#### DATA SOURCE

Administrative data\
Medical record

#### LEVEL OF DETERMINATION OF QUALITY

Not Individual Case

#### OUTCOME TYPE

Adverse Outcome

#### PRE-EXISTING INSTRUMENT USED

Unspecified

### Computation of the Measure

#### SCORING

Rate

#### INTERPRETATION OF SCORE

Better quality is associated with a lower score

#### ALLOWANCE FOR PATIENT FACTORS

Unspecified

#### STANDARD OF COMPARISON

External comparison at a point in time\
External comparison of time trends\
Internal time comparison

### Evaluation of Measure Properties

#### EXTENT OF MEASURE TESTING

Unspecified

### Identifying Information

#### ORIGINAL TITLE

Indicator area 2: morbidity of radiological procedures CI 2.1.

#### MEASURE COLLECTION

[Australian Council on Healthcare Standards (ACHS) Equip Clinical
Indicators](http://www.qualitymeasures.ahrq.gov/Browse/DisplayOrganization.aspx?org_id=1984&doc=11061)

#### MEASURE SET NAME

[Radiology
Indicators](http://www.qualitymeasures.ahrq.gov/Browse/DisplayOrganization.aspx?org_id=1984&doc=11265)

#### DEVELOPER

Australian Council on Healthcare Standards

#### FUNDING SOURCE(S)

Funding is direct Australian Council on Healthcare Standards (ACHS)
funding sourced through our membership. ACHS does not receive external
funding from the government or other sources.

#### COMPOSITION OF THE GROUP THAT DEVELOPED THE MEASURE

Our terms of reference dictate the composition of the working parties
that develop our indicators and include the following:

-   Two Clinicians \-- nominated by the relevant specialty
    college/association/society, one nominated to be the chair of the
    working party

-   Private Hospital Representative \-- nominated by the Australian
    Private Hospital Association

-   Consumer Representative \-- nominated by the Consumer Health Forum
    of Australia

-   Coding Representative \-- nominated by the National Centre for
    Clinical classification on Health

-   Quality Health New Zealand, nominated by QHNZ (if applicable)

-   Epidemiological/Clinical Research Representative, Director of Health
    Services Research Group, University of Newcastle

-   Australian Council on Healthcare Standards (ACHS) Representatives
    \-- Clinical Director, Coordinator, Administrative Assistant

-   Other Expert Stakeholders, as required

#### FINANCIAL DISCLOSURES/OTHER POTENTIAL CONFLICTS OF INTEREST

None

#### ADAPTATION

Measure was not adapted from another source.

#### RELEASE DATE

1997 Sep

#### REVISION DATE

2007 Dec

#### MEASURE STATUS

This is the current release of the measure.

#### SOURCE(S)

Australian Council on Healthcare Standards (ACHS). ACHS clinical
indicator users\' manual 2008. ULTIMO NSW: Australian Council on
Healthcare Standards (ACHS); 2007 Dec. 776 p.

#### MEASURE AVAILABILITY

The individual measure, \"Indicator Area 2: Morbidity of Radiological
Procedures CI 2.1,\" is published in \"ACHS Clinical Indicator Users\'
Manual 2008.\"

For more information contact, the Australian Council on Healthcare
Standards (ACHS), 5 Macarthur Street, ULTIMO NSW 2007; Phone: (02) 9281
9955; Fax: (02) 9211 9633; E-mail: <pos@achs.org.au>; Web site:
[www.achs.org.au](http://www.achs.org.au/).

#### COMPANION DOCUMENTS

The following is available:

-   Australian Council on Healthcare Standards (ACHS). Australian
    clinical indicator report 1998-2006. Determining the potential to
    improve quality of care: 8th edition. ULTIMO NSW: Australian Council
    on Healthcare Standards (ACHS); 2007. 564 p. This document is
    available in Portable Document Format (PDF) from the [Australian
    Council on Healthcare Standards (ACHS) Web
    site](http://www.achs.org.au/pdf/Australasian_CIR_8th_Edition.pdf).

#### NQMC STATUS

This NQMC summary was completed by ECRI Institute on January 16, 2008.

#### COPYRIGHT STATEMENT

This NQMC summary is based on the original measure, which is subject to
the measure developer\'s copyright restrictions. This work is copyright.
Apart from any use as permitted under the Copyright Act 1968, no part
may be reproduced by any process without written permission from The
Australian Council on Healthcare Standards (ACHS).

### Disclaimer

#### NQMC DISCLAIMER

The National Quality Measures Clearinghouse™ (NQMC) does not develop,
produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced
under the auspices of medical specialty societies, relevant professional
associations, public and private organizations, other government
agencies, health care organizations or plans, individuals, and similar
entities.

Measures represented on the NQMC Web site are submitted by measure
developers, and are screened solely to determine that they meet the NQMC
Inclusion Criteria which may be found at
<http://www.qualitymeasures.ahrq.gov/about/inclusion.aspx>.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties
concerning the content or its reliability and/or validity of the quality
measures and related materials represented on this site. The inclusion
or hosting of measures in NQMC may not be used for advertising or
commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact
the measure developer.

Bottom of Form

© 2008 National Quality Measures Clearinghouse

Date Modified: 11/3/2008